Announcement by the Bicycle therapeutics that the presentation at the ESMO 2019 Annual Congress of updated data from the Phase I / IIa trial evaluating BT1718 in patients with advanced solid tumors

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology firm pioneering a new therapeutic class based on its proprietary bicyclic peptide (Bicycles ®) product platform, announced today the introduction of updated information from a Phase I / IIa trial in cooperation with…

Aristea: Scientific Advisory Board

Aristea Therapeutics (Aristea) is clinical-stage drug development company that develops novel therapies for treating serious inflammatory diseases. Today it made the announcement about its Scientific Advisory Board (SAB), which comprises of industry experts in inflammatory and dermatological disease drug development.…